Fundamental Analysis of BIOCARDIA INC(NASDAQ:BCDA) stock

Fundamental Rating

Taking everything into account, BCDA scores 1 out of 10 in our fundamental rating. BCDA was compared to 588 industry peers in the Biotechnology industry. BCDA may be in some trouble as it scores bad on both profitability and health. BCDA is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

BCDA had negative earnings in the past year.

BCDA had a negative operating cash flow in the past year.

In the past 5 years BCDA always reported negative net income.

BCDA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of BCDA (-387.08%) is worse than 95.56% of its industry peers.

		Industry Rank	Sector Rank
ROA	-387.08%
ROE	N/A
ROIC	N/A

ROA(3y)-196.44%

ROA(5y)-168.98%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BCDA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BCDA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for BCDA has been increased compared to 1 year ago.

Compared to 5 years ago, BCDA has more shares outstanding

BCDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -83.58, we must say that BCDA is in the distress zone and has some risk of bankruptcy.

BCDA has a worse Altman-Z score (-83.58) than 96.76% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-83.58

ROIC/WACCN/A

WACC9.22%

2.3 Liquidity

A Current Ratio of 0.40 indicates that BCDA may have some problems paying its short term obligations.

The Current ratio of BCDA (0.40) is worse than 95.90% of its industry peers.

A Quick Ratio of 0.40 indicates that BCDA may have some problems paying its short term obligations.

BCDA's Quick ratio of 0.40 is on the low side compared to the rest of the industry. BCDA is outperformed by 95.56% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.4
Quick Ratio	0.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BCDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.91%, which is quite good.

Looking at the last year, BCDA shows a very negative growth in Revenue. The Revenue has decreased by -64.96% in the last year.

BCDA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.41% yearly.

EPS 1Y (TTM)17.91%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q43.75%

Revenue 1Y (TTM)-64.96%

Revenue growth 3Y47.05%

Revenue growth 5Y-5.41%

Revenue growth Q2Q-88.18%

3.2 Future

The Earnings Per Share is expected to grow by 17.32% on average over the next years. This is quite good.

The Revenue is expected to grow by 150.49% on average over the next years. This is a very strong growth

EPS Next Y-4.78%

EPS Next 2Y-21.42%

EPS Next 3Y-6.15%

EPS Next 5Y17.32%

Revenue Next Year-39.86%

Revenue Next 2Y79.61%

Revenue Next 3Y154.05%

Revenue Next 5Y150.49%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCDA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCDA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BCDA's earnings are expected to decrease with -6.15% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-21.42%

EPS Next 3Y-6.15%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BCDA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOCARDIA INC

NASDAQ:BCDA (5/3/2024, 7:00:01 PM)

After market: 0.375 0 (-1.29%)

0.3799

+0 (+1.31%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap10.21M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-387.08%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.16

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.4
Quick Ratio	0.4
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)17.91%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-4.78%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-64.96%

Revenue growth 3Y47.05%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BIOCARDIA INC (BCDA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens